Recently stock market analysts have updated their consensus ratings on shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP). The latest broker reports which are currently outstanding on Monday 9th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

02/25/2016 – Citigroup began new coverage on Adaptimmune Therapeutics plc giving the company a “buy” rating. They now have a USD 15 price target on the stock.

12/22/2015 – SunTrust began new coverage on Adaptimmune Therapeutics plc giving the company a “buy” rating. They now have a USD 16 price target on the stock.

10/15/2015 – Adaptimmune Therapeutics plc had its “outperform” rating reiterated by analysts at Cowen.

06/30/2015 – Adaptimmune Therapeutics plc had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 24 price target on the stock.

06/01/2015 – Bank of America Merrill Lynch began new coverage on Adaptimmune Therapeutics plc giving the company a “neutral” rating. They now have a USD 17 price target on the stock.

06/01/2015 – Guggenheim began new coverage on Adaptimmune Therapeutics plc giving the company a “buy” rating. They now have a USD 25 price target on the stock.

Adaptimmune Therapeutics plc has a 50 day moving average of 8.98 and a 200 day moving average of 9.13. The stock’s market capitalization is 615.12M, it has a 52-week low of 6.19 and a 52-week high of 21.57.

The share price of the company (NASDAQ:ADAP) was down -0.69%, with a high of 8.82during the day and the volume of Adaptimmune Therapeutics plc shares traded was 124155.

View other investors thoughts on Adaptimmune Therapeutics plc with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.